vimarsana.com

Page 21 - மருத்துவ புற்றுநோயியல் நிபுணர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sigara kansere davetiye çıkarıyor

Sigara kansere davetiye çıkarıyor
istanbulhaber.com.tr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from istanbulhaber.com.tr Daily Mail and Mail on Sunday newspapers.

Solon seeks ban on teenage smoking: Lung cancer can be prevalent like COVID-19 – Manila Bulletin

Solon seeks ban on teenage smoking: Lung cancer can be prevalent like COVID-19 – Manila Bulletin
mb.com.ph - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mb.com.ph Daily Mail and Mail on Sunday newspapers.

Non-Invasive Liquid Biopsy to Help Cancer Diagnosis Gets CE Certification

Non-Invasive Liquid Biopsy to Help Cancer Diagnosis Gets CE Certification

Non-Invasive Liquid Biopsy to Help Cancer Diagnosis Gets CE Certification
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

Health Canada Approves KEYTRUDA® (pembrolizumab) as First-line Treatment for Adults with Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer

KEYTRUDA ® is an anti-PD-1 therapy that works by helping increase the ability of the body s immune system to help detect and fight tumour cells. 1 An estimated 26,900 Canadians were diagnosed with colorectal cancer in 2020, with an average of 73 Canadians diagnosed daily. 2 KIRKLAND, QC, March 8, 2021 /CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Health Canada has approved KEYTRUDA ® (pembrolizumab), Merck s anti-PD-1 therapy, for the first-line treatment, as monotherapy, for adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC). 3 This approval offers a new first-line treatment option for patients with MSI-H/dMMR metastatic colorectal cancer, said Dr. Ron Burkes, Professor of Medicine, University of Toronto and Medical Oncologist, Mount Sinai Hospital.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.